{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-22-000054","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.135882+00:00","generated_at":"2026-06-27T05:04:05.422555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Chemed Q4 2021 adj EPS $5.25, up 2.3%; VITAS revenue down 4.8%; issues mixed 2022 guidance","bullets":["Consolidated Q4 revenue $541M (+1.4%); GAAP diluted EPS $4.81; adjusted diluted EPS $5.25 (+2.3%).","VITAS net revenue $316M (-4.8%), ADC 17,935 (-4.2%), admissions down 9.5%; adjusted EBITDA margin 21.7% (-179 bps).","Roto-Rooter revenue $225M (+11.8%); adjusted EBITDA $62.2M (+14.2%); margin 27.7% (+58 bps).","2022 guidance: adjusted EPS $19.10-$19.50 (vs 2021 $19.33); VITAS revenue down 1.5-2.5%; Roto-Rooter revenue growth 8-9.5%.","Q4 share repurchases: 495,529 shares for $246M; $202M remaining authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-22-000054","json":"https://secwatch.observer/filing/0001562762-22-000054.json","markdown":"https://secwatch.observer/filing/0001562762-22-000054.md","text":"https://secwatch.observer/filing/0001562762-22-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276222000054/0001562762-22-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276222000054/che-20220224x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:04:05.422555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}